Solid-state analysis of the active pharmaceutical ingredient in drug products

2003 ◽  
Vol 8 (19) ◽  
pp. 898-905 ◽  
Author(s):  
Ann W. Newman ◽  
Stephen R. Byrn
2001 ◽  
Vol 27 (9) ◽  
pp. 943-949 ◽  
Author(s):  
Hideshi Suzuki ◽  
Masahiro Ogawa ◽  
Kenji Hironaka ◽  
Kunio Ito ◽  
Hisakazu Sunada

2018 ◽  
Vol 266 ◽  
pp. 95-105 ◽  
Author(s):  
Abhishek Rai ◽  
Alok Kumar Singh ◽  
Kamini Tripathi ◽  
Avinash Kumar Sonkar ◽  
Brijesh Singh Chauhan ◽  
...  

Author(s):  
A.V.S. Ksheera Bhavani ◽  
A. Lakshmi Usha ◽  
Kayala Ashritha ◽  
Radha Rani E.

Poor aqueous solubility and low oral bioavailability of an active pharmaceutical ingredient are the major constraints during the development of new product. Various approaches have been used for enhancement of solubility of poorly aqueous soluble drugs, but success of these approaches depends on physical and chemical nature of the molecules being developed. Co-crystallization of drug substances offers a great opportunity for the development of new drug products with superior physicochemical such as melting point, tabletability, solubility, stability, bioavailability and permeability, while preserving the pharmacological properties of the active pharmaceutical ingredient. Co-crystals are multi component systems in which two components, an active pharmaceutical ingredient and a coformer are present in stoichiometric ratio and bonded together with non-covalent interactions in the crystal lattice. This review article presents a systematic overview of pharmaceutical co-crystals, differences between co-crystals with salts, solvates and hydrates are summarized along with the advantages of co-crystals with examples. The theoretical parameters underlying the selection of coformers and screening of co-crystals have been summarized and different methods of co-crystal formation and evaluation have been explained.


2020 ◽  
Vol 30 ◽  
pp. 100577
Author(s):  
N.K. Manjunatha ◽  
Mahesha ◽  
B.H. Gayathri ◽  
N.K. Lokanath ◽  
M.T. Swamy ◽  
...  
Keyword(s):  

2013 ◽  
Vol 69 (12) ◽  
pp. 1516-1523 ◽  
Author(s):  
K. Ravikumar ◽  
B. Sridhar ◽  
Jagadeesh Babu Nanubolu ◽  
A. K. S. Bhujanga Rao ◽  
R. Jyothiprasad

Two tosylate salts of an anticancer drug lapatinib,viz. a monotosylate [systematic name: ({5-[4-({3-chloro-4-[(3-fluorophenyl)methoxy]phenyl}amino)quinazolin-6-yl]furan-2-yl}methyl)[2-(methylsulfonyl)ethyl]azanium 4-methylbenzenesulfonate], C29H27ClFN4O4S+·C7H7O3S−, (I), and a ditosylate [systematic name: 4-({3-chloro-4-[(3-fluorophenyl)methoxy]phenyl}amino)-6-]5-({[2-(methylsulfonyl)ethyl]azaniumyl}methyl)furan-2-yl[quinazolin-1-ium bis(4-methylbenzenesulfonate)], C29H28ClFN4O4S2+·2C7H7O3S−, (II), were obtained during crystallization attempts for polymorphism. In both structures, the lapatinib cation is in a distorted U-like conformation and the tosylate anion is clamped between the aniline N atom and methylamine N atom through N—H...O hydrogen bonds, forming anR22(15) ring motif. The 4-anilinoquinazoline ring system is essentially planar in (I), while it is twisted in (II), controlled by an intramolecular C—H...N interaction. In (I), alternating cations and anions are linked by N—H...O hydrogen bonds intoC22(6) chains. These chains are linked by cations in a helical manner. The presence of the additional tosylate anion in (II) results in the formation of one-dimensional tapes of fused hydrogen-bonded rings through N—H...O and C—H...O interactions. These studies augment our understanding of the role of nonbonded interactions in the solid state, which is useful for correlation to the physicochemical properties of drug products.


ACS Omega ◽  
2020 ◽  
Vol 5 (39) ◽  
pp. 25289-25296
Author(s):  
Penghui Yuan ◽  
Dezhi Yang ◽  
Ruonan Wang ◽  
Ningbo Gong ◽  
Li Zhang ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document